Core Viewpoint - Huazhan Biotech is at a critical juncture with no stable income, no commercialized products, and no profitability, despite significant investment and a long development period. The company is under pressure to go public on the Hong Kong Stock Exchange to resolve its current challenges [1] Company Overview - Established in 2012, Huazhan Biotech focuses on developing protein drugs for wound healing, specifically targeting platelet-derived growth factor (PDGF) drugs. The company aims to fill a gap in the domestic market, as there are very few PDGF drugs available globally [2][3] Product Pipeline - Huazhan Biotech has three research pipelines with ten candidate products covering 14 indications, seven of which are PDGF drugs. Key products include Pro-101-1 for burns and Pro-101-2 for diabetic foot ulcers, with clinical trials at various stages [3][4] Market Potential - The potential market for PDGF drugs in China is limited, with the projected market size for burn-related PDGF drugs only about 6.66 million yuan by 2033. The diabetic foot ulcer treatment market is larger, estimated at 580 million yuan, but competition is significant with multiple companies developing similar products [4][5] Financial Performance - The company reported revenues of 472,000 yuan, 261,000 yuan, and 0 yuan for 2023, 2024, and the first five months of 2025, respectively, with net losses of 105 million yuan, 212 million yuan, and 72 million yuan during the same periods. Administrative expenses are notably high, exceeding research and development costs [9][10] Cash Flow and Funding - As of May 31, 2025, Huazhan Biotech's cash and cash equivalents dropped to 105 million yuan, with a burn rate suggesting that current funds could sustain operations for about six months. The company has no major external debt financing plans and is under pressure to complete an IPO by December 31, 2026, due to clauses in previous funding rounds [10]
华芢\生物成立13年来无药上市 背负对赌协议闯关港交所
Mei Ri Jing Ji Xin Wen·2025-09-15 15:41